Cytek Biosciences, Inc. (CTKB) intrinsic value & 10-year financials
Cytek Biosciences, Inc. (CTKB) has a Graham intrinsic value of $0.66 per share. At $5.25 on Oct 17, 2026, the stock trades 695% above that value. Over the last 7 fiscal years revenue grew 16.8% a year to $201.5M, with an average return on invested capital of -11.8%.
- Graham intrinsic value
- $0.66
- Share price (Oct 17, 2026)
- $5.25
- Price vs Graham value
- 695% above
- Market cap
- $670.7M
- Revenue (FY2025)
- $201.5M
- Revenue growth (7-yr CAGR)
- 16.8%
- ROIC (10-yr avg)
- -11.8%
- Free cash flow (FY2025)
- -$8.8M
CTKB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $201.5M | -$66.5M | — | -$8.8M | -20.0% | -14.2% |
| FY2024 | $200.5M | -$6.0M | — | $21.9M | -10.2% | -7.6% |
| FY2023 | $193.0M | -$12.1M | -$0.09 | $633.0K | -14.4% | -11.4% |
| FY2022 | $164.0M | $2.5M | $0.02 | -$22.0M | -1.1% | -2.0% |
| FY2021 | $128.0M | $3.0M | $0.00 | $266.0K | 7.2% | 11.5% |
| FY2020 | $92.8M | $19.4M | $0.10 | $13.6M | 14.7% | -47.3% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cytek Biosciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Cytek Biosciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -4.8% ROIC.
Cytek Biosciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Cytek Biosciences, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.66 per share.